Literature DB >> 18923747

Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis.

K A Paschos1, N Bird.   

Abstract

Colorectal cancer is the second leading cause of cancer death in the developed world, due to formation of distant metastases. The liver is a primary target organ of metastatic lesions, which substantially influence the morbidity of the disease. Prompt diagnosis of colorectal liver metastases leads to early treatment, which favours a better prognosis. Consequently, the diagnostic process has shifted from traditional clinical and biochemical procedures to technologically advanced imaging modalities, such as CT, MRI, FDG-PET and PET-CT. However, the only current curative therapeutic approach is the surgical resection of metastases, using the new methods of tissue excision and haemostasis. New therapeutic modalities like cryo- or radiofrequency ablation and portal vein embolisation as well as pharmaceutical innovations such as hepatic arterial infusion chemotherapy, isolated hepatic perfusion and contemporary chemotherapeutic regimens have emerged. While still under evaluation, they present promise for the future treatment of unresectable liver metastases.

Entities:  

Keywords:  ablation; chemotherapy; colorectal cancer; liver metastasectomy; liver metastasis

Year:  2008        PMID: 18923747      PMCID: PMC2504407     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  56 in total

1.  Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study.

Authors:  Daniel Jaeck; Hiroshi Nakano; Philippe Bachellier; Keiichiro Inoue; Jean-Christophe Weber; Elie Oussoultzoglou; Philippe Wolf; Marie-Pierre Chenard-Neu
Journal:  Ann Surg Oncol       Date:  2002-06       Impact factor: 5.344

2.  Guidelines for resection of colorectal cancer liver metastases.

Authors:  O J Garden; M Rees; G J Poston; D Mirza; M Saunders; J Ledermann; J N Primrose; R W Parks
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

3.  Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect.

Authors:  Dominique Elias; Gabriel Liberale; Déwi Vernerey; Marc Pocard; Michel Ducreux; Valérie Boige; David Malka; Jean-Pierre Pignon; Philippe Lasser
Journal:  Ann Surg Oncol       Date:  2005-09-26       Impact factor: 5.344

4.  The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth.

Authors:  N B Ackerman
Journal:  Surgery       Date:  1974-04       Impact factor: 3.982

5.  [Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases--the International Registry of Lung Metastases].

Authors:  G Friedel; U Pastorino; M Buyse; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam; H Toomes
Journal:  Zentralbl Chir       Date:  1999       Impact factor: 0.942

Review 6.  Evidence-base guideline on management of colorectal liver metastases in the Netherlands.

Authors:  S Bipat; M S van Leeuwen; J N M Ijzermans; E F I Comans; A S Th Planting; P M M Bossuyt; J-W Greve; J Stoker
Journal:  Neth J Med       Date:  2007-01       Impact factor: 1.422

7.  Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis.

Authors:  Robert Martin; Philip Paty; Yuman Fong; Andrew Grace; Alfred Cohen; Ronald DeMatteo; William Jarnagin; Leslie Blumgart
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

Review 8.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

Authors:  R Adam
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

9.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

10.  Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.

Authors:  A Wein; C Riedel; W Brückl; S Merkel; R Ott; B Hanke; U Baum; F Fuchs; K Günther; T Reck; T Papadopoulos; E G Hahn; W Hohenberger
Journal:  Oncology       Date:  2003       Impact factor: 2.935

View more
  7 in total

1.  Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates.

Authors:  Ayumi Hamada; Koichiro Yamakado; Atsuhiro Nakatsuka; Junji Uraki; Masataka Kashima; Haruyuki Takaki; Takashi Yamanaka; Yasuhiro Inoue; Masato Kusunoki; Kan Takeda
Journal:  Jpn J Radiol       Date:  2012-06-05       Impact factor: 2.374

2.  Correlation between calcified liver metastases and histopathology of primary colorectal carcinoma in Chinese.

Authors:  Liying Xu; Yunfeng Zhou; Dasheng Qiu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

3.  Socioeconomic status influences the likelihood but not the outcome of liver resection for colorectal liver metastasis.

Authors:  Matthew G Wiggans; Golnaz Shahtahmassebi; Somaiah Aroori; Matthew J Bowles; David A Stell
Journal:  HPB (Oxford)       Date:  2014-07-03       Impact factor: 3.647

4.  Serological diagnostic factors for liver metastasis in patients with colorectal cancer.

Authors:  Xiong-Zhi Wu; Feng Ma; Xue-Lin Wang
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

5.  Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.

Authors:  S Gill; S Berry; J Biagi; C Butts; M Buyse; E Chen; D Jonker; C Mărginean; B Samson; J Stewart; M Thirlwell; R Wong; J A Maroun
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

6.  Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer.

Authors:  Bang Hu; Donglin Ren; Dan Su; Hongcheng Lin; Zhenyu Xian; Xingyang Wan; Junxiao Zhang; Xinhui Fu; Li Jiang; Dechan Diao; Xinjuan Fan; Lei Wang; Jianping Wang
Journal:  BMC Cancer       Date:  2012-03-30       Impact factor: 4.430

7.  CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer.

Authors:  Chao Fang; Chuanwen Fan; Cun Wang; Qiaorong Huang; Wentong Meng; Yongyang Yu; Lie Yang; Zhihai Peng; Jiankun Hu; Yuan Li; Xianming Mo; Zongguang Zhou
Journal:  Oncotarget       Date:  2016-11-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.